

ORIGINAL RESEARCH

The influence of frailty syndrome on acceptance of illness in elderly patients with chronic obstructive pulmonary disease

Izabella Uchmanowicz¹ Beata Jankowska-Polanska¹ Mariusz Chabowski² Bartosz Uchmanowicz¹ Andrzej M Fal³

Department of Clinical Nursing, Faculty of Health Science, Wroclaw Medical University, ²Division of Nursing in Surgical Procedures, Department of Clinical Nursing, Faculty of Health Science, Wroclaw Medical University, 3Department of Healthcare Organisation and Economics, National Institute of Public Health, National Institute of Hygiene, Warsaw, Poland

Abstract: COPD is one of the most debilitating diseases. Frailty syndrome and advanced age may decrease the acceptance of illness, quality of life, and worsen health conditions in these patients, as well as lead to an increase in health care expenses. The aim of the study was to assess how the level of frailty affects the acceptance of illness in elderly patients with COPD. We also aimed to evaluate the associations between sociodemographic and clinical factors and the level of acceptance of illness, anxiety, and frailty in this group of patients. The study included 102 COPD patients with a mean age of 63.2 (standard deviation =6.5) years and grades I (3%), II (37%), III (52%), and IV (8%) by Global Initiative for Chronic Obstructive Lung Disease. The Polish versions of the Acceptance of Illness Scale and Tilburg frailty indicator were used. Frailty syndrome was found in 77 (75.5%) patients, with an average score of 7.42 (standard deviation =2.24). Coexisting diseases such as hypertension (46.07%), coronary artery disease (32.35%), heart failure (28.43%), diabetes (18.63%), and heart arrhythmia (9.8%) were found among the subjects. The overall level of acceptance of illness was 20.6 (standard deviation =7.62). A lower level of acceptance of illness was associated with a higher level of frailty, especially in the physical and social domain. Elderly patients with severe COPD are more prone to frailty and decreased acceptance of their disease in comparison to patients with other chronic diseases. Assessment and management of frailty in the care of older COPD patients are likely to improve risk stratification significantly and help personalize management, leading to better patient outcomes.

Keywords: frailty syndrome, COPD, acceptance of illness, elderly patients, Tilburg frailty indicator, TFI, Acceptance of Illness Scale, AIS

Introduction

COPD in one of the most important public health problems and one of the most common chronic diseases. 1 It is estimated that, in Poland, about 2 million patients suffer from COPD; 80% of them have either mild or moderate severity airflow limitation. The remaining 20%, with severe and very severe airflow limitation, require increased use of medical care.² COPD is currently the fourth most common cause of death among adult patients worldwide, but morbidity and mortality are constantly increasing.³ It has been projected that, by 2020, COPD will be the third most common cause of diseaserelated deaths.^{4,5} In the population of >60 years of age, COPD is a serious problem because diagnosis is often delayed by nonspecific symptoms. In elderly people with advanced COPD, exacerbations occur more frequently than in younger populations and are associated with an increased risk of acute respiratory failure. Polypharmacy, which is common in elderly patients, may additionally increase the risk of side effects

Correspondence: Mariusz Chabowski Department of Surgery, 4th Military Teaching Hospital, 5 Weigla Street, 50-981 Wroclaw, Poland Tel +48 261 660 247 Fax +48 261 660 245 Email mariusz.chabowski@gmail.com

as these patients take many drugs for numerous diseases. Polypharmacy and possible drug interactions may hamper disease management. Elderly patients with COPD are also at an increased risk of developing frailty syndrome (FS) and problems with disease acceptance.^{6,7}

FS often coexists with chronic diseases. It increases the risk of adverse health events and is strongly associated with a decrease in mobility, an increased risk of falls, polypharmacy, comorbidities, a decrease in cognitive function, and malnutrition.⁸ On the one hand, FS can be regarded as a consequence of aging, but on the other, it is associated with many chronic diseases that increase patient disability, hospitalization rates, costs of health care, and mortality. To date, frailty has been assessed in patients with many chronic diseases, such as cardiovascular diseases, obesity, renal insufficiency, but little is known about the coexistence of frailty with COPD in elderly patients.^{8–11} Moreover, the impact of FS on the acceptance of illness in elderly COPD patients remains unclear.

The aim of the study was to assess how the level of frailty affects the acceptance of illness in elderly patients with COPD. We also aimed to evaluate the associations between sociodemographic and clinical factors and the level of acceptance of illness, anxiety, and frailty in this group of patients.

Methods

The study was conducted among 102 patients with COPD hospitalized due to exacerbation of their condition in the Department of Internal Medicine of Lower Silesian Centre for Pulmonary Diseases in Wroclaw between March 2014 and June 2015. Participation in the study was both voluntary and confidential. All the patients were informed about the aims of the study and the right to withdraw from the research at any time. The study was approved by the Commission of Bioethics at Wroclaw Medical University (consent no KB-683/2014).

Inclusion criteria were as follows:

- Diagnosis of COPD according to the American Thoracic Society/European Respiratory Society in the history at least 1 year before entering the study.¹²
- Written informed consent for participation in the study. Exclusion criteria were as follows:
- Coexistence of other chronic pulmonary disease such as asthma, active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, pulmonary fibrosis, primary pulmonary hypertension, interstitial lung disease, or other active lung disease.

- 2. Hemodynamic instability and severe exacerbation of any concomitant chronic disease.
- 3. The diagnosis of severe mental disorders requiring psychiatric treatment.
- 4. Lack of consent for participation in the study.

In this study, an integral model of frailty developed by Gobbens was used as a conceptual basis. This model was chosen because it incorporates a more holistic approach to frailty going beyond the physical approach, which is the basis for most models of frailty. The conceptual model defines frailty using indicators from three domains: physical, psychological, and social.¹³

In the study, standardized questionnaires were used and an analysis of medical records was done in order to collect information about diagnosis, severity of the disease, spirometry results, and treatment administered.

- The survey produced by the authors included 18 questions related to sociodemographic and clinical data (sex, age, education, number of cigarettes smoked, frequency of hospitalizations, knowledge about the disease, and drugs administered by inhalation).
- 2. The Acceptance of Illness Scale (AIS) developed by Felton et al and adapted to Polish conditions by Jurczyński included eight statements and allowed assessment of the degree of illness acceptance by the patient. ^{14,15} The greater the acceptance of the disease, the less severe the negative reactions and emotions associated with the disease. Each of the statements included a 5-score scale. The patients described their current well-being by indicating the corresponding number: 1 strongly agree; 2 agree; 3 undecided; 4 disagree; 5 strongly disagree. Wherein, 1 means a bad adaptation to disease and 5 the highest acceptance of the given condition. The adaptation to the disease is the sum of all the points and is between 8 and 40 points. The authors believe it can be applied to assess any type of disease. ¹⁴
- 3. The Tilburg frailty indicator (TFI) consists of two different parts. One addresses potential determinants of frailty: the participant's sociodemographic characteristics (sex, age, marital status, country of origin, educational level, and monthly income), lifestyle, multimorbidity, life events, and living environment. The second part addresses the components of frailty. Part two of the TFI comprises 15 self-reported questions, divided into three domains. The physical domain (0–8 points) consists of eight questions related to physical health, unexplained weight loss, difficulty in walking, balance, hearing problems, vision problems, strength in hands, and physical tiredness. The psychological domain

(0–4 points) comprises four items related to cognition, depressive symptoms, anxiety, and coping. The social domain (0–3 points) comprises three questions related to living alone, social relations, and social support. Eleven items in part two of the TFI have two response categories ("yes" and "no"), while the other items have three ("yes", "no", and "sometimes"). "Yes" or "sometimes" responses are scored 1 point each, while "no" responses are scored 0. The instrument's total score may range from 0 to 15: the higher the score, the higher one's frailty. Frailty is diagnosed when the total TFI score is ≥ 5.16 In the present study, the Polish version of the TFI questionnaire was used. 17

Statistical analysis

The results were analyzed with Statistica software version 6 (StatSoft, Tulsa, OK, USA). Means, medians, and standard deviations (SDs) were calculated for the variables examined. To assess the differences, Student's *t*-test was applied. Two-way analysis of variance allowed the impact of frailty on acceptance of the disease to be estimated. Pearson's correlation was used to measure the correlation between sociodemographic and clinical variables and the levels of illness acceptance (AIS), anxiety, and frailty (TFI).

Results

The study was conducted in 102 patients with COPD, of whom 37.25% were women. The average age of those surveyed was 63.2 years (SD =6.5). More than one-half of the respondents were married or lived in partnerships (57.8%). The majority lived in cities (60.8%) and had secondary (55.6%) or vocational (26.5%) education. They received knowledge about the disease from medical personnel (39.2% from nurses and 37.3% from doctors). More than one-half of the respondents (58.8%) claimed that the level of their knowledge was insufficient (Table 1).

The majority of the patients had suffered from COPD for 10–15 years (33.3%). Subsequently, there were people with a 5- to 10-year disease history (27.5%) and those who had been ill for more than 15 years (22.6%). Most patients were at the III (severe) (52%) and II (moderate) (37%) stage of disease by Global Initiative for Chronic Obstructive Lung Disease. Spirometric classification for the group was: forced expiratory volume in 1 second 1.36, forced vital capacity 49% N, and fixed ratio (forced expiratory volume in 1 second/forced vital capacity) 0.61. All the patients were exposed to the main risk factor of COPD and 50% of respondents had smoked for longer than 15 years. Fewer than 30% of respondents smoked up to ten cigarettes per day, the

Table I Sociodemographic characteristics of the studied patients

0 1		
Characteristics	N	%
Sex		
Men	64	62.75
Women	38	37.25
Marital status		
Married/in a relationship	59	57.84
Separated/divorced	22	22.57
Widow/widower	21	20.59
Education		
Vocational/primary	27	26.47
Preuniversity	57	55.88
Higher vocational/university	14	13.73
Data not available	4	3.92
Place of residence		
Rural area	40	39.22
Urban area	62	60.78
Knowledge about COPD		
I believe I know everything on this topic	7	6.86
I know as much as I need to know	33	32.35
I know too little	60	58.82
I do not know and I do not want to know	2	1.96
The most useful sources of information helpful in	coping	
with the disease		
Conversation with a doctor	38	37.25
Conversation with a nurse	40	39.21
Books, leaflets	19	18.63
Television	5	4.9

Abbreviation: N, number of patients.

others smoked 10–20 (39.2%) or even more than 20 (31.4%); 40.2% of patients reported aggravation of symptoms more than twice a day, 16.7% every day, and 24.5% several times a week. More than one-half of the respondents (55.9%) complained of waking up from sleep due to being short of breath three nights or more a week. Only 16.7% of respondents reported no symptoms during the night. Among the subjects, 64.7% believed that they take inhaled medications skillfully, 10.8% of them were given oxygen therapy at home, and over 60% had been hospitalized during the past 12 months due to exacerbations. In addition, the respondents' diagnosed comorbidities included hypertension (46.07%), coronary artery disease (32.35%), heart failure (28.43%), diabetes (18.63%), and heart arrhythmia (9.8%) (Table 2).

The assessment of illness acceptance with the use of AIS questionnaire revealed that respondents are mostly characterized by a moderate acceptance level with a tendency to a lack of acceptance of their disease (mean 20.6; SD =7.62). Patients worried most about the limitation of their self-sufficiency (mean 2.2; SD =1.20), but least about being a burden on their family and friends (mean 3.1; SD =1.10) (Table 3).

FS was found in 77 patients. The minimal TFI score was 3, maximum 12, and average 7.42 (SD =2.24) (Table 4).

Table 2 Clinical characteristics of the studied patients

Spirometry Mean (SD) Range FEV, (L) 1.36 (0.7) 0.51–3.50 FEV, %N 49 (16.3) 15–87 Ratio of FEV, to FVC (Tiffeneau index) 0.61 (0.17) 0.41–0.7 Characteristics N % Duration of the disease -5 years 17 16.67 5–10 years 28 27.45 10–15 years 34 33.33 Longer than 15 years 23 22.55 Disease severity by GOLD 3 3 3 III 38 37 III 53 52 IV 8 8 Comorbidities 8 Comorbidities 8 Comorbidities 47 46.07 46.07 Coronary artery disease 33 32.35 Heart failure 29 28.43 20.32 22.21 22.57 22.43 23.25 23.25 23.25 23.25 23.25 23.25 23.25 23.23 23.25 23.25 23.25 25.5 24.51 20.07 29.41 29.2 28.43 29.25 24	Clinical characteristics			
FEV % N Ratio of FEV to FVC (Tiffeneau index) 0.61 (0.17) 0.41-0.7	Spirometry	Mean (SD)	Range	
Ratio of FEV₁ to FVC (Tiffeneau index) 0.61 (0.17) 0.41-0.7 Characteristics N % Duration of the disease	FEV ₁ (L)	1.36 (0.7)	0.51-3.50	
Ratio of FEV₁ to FVC (Tiffeneau index) N. %41–0.7 Characteristics N. % Duration of the disease 17 16.67 0-5 years 17 16.67 5-10 years 28 27.45 10-15 years 34 33.33 Longer than 15 years 23 22.55 Disease severity by GOLD T 3 3 II 38 37 11 II 38 37 11 II 53 52 12 IV 8 8 8 Comorbidities W 47 46.07 <t< td=""><td>FEV, %N</td><td>49 (16.3)</td><td>15-87</td></t<>	FEV, %N	49 (16.3)	15-87	
Duration of the disease 17 16.67 5-10 years 28 27.45 10-15 years 34 33.33 Longer than 15 years 23 22.55 Disease severity by GOLD 3 3 I 38 37 III 38 37 III 53 52 IV 8 8 Comorbidities 47 46.07 Hypertension 47 46.07 Coronary artery disease 33 32.35 Heart failure 29 28.43 Diabetes 19 18.63 Heart arrhythmia 10 9.80 Duration of smoking 2 2 21.57 5-10 years 9 8.82 10-15 years 9 8.82 10-15 years 20 19.61 Longer than 15 years 51 50.00 The number of cigarettes smoked per day 0-10 30 29.41 10-20 40		0.61 (0.17)	0.41-0.7	
0-5 years 17 16.67 5-10 years 28 27.45 10-15 years 34 33.33 Longer than 15 years 23 22.55 Disease severity by GOLD 1 3 3 II 38 37 III 53 52 IV 8 8 Comorbidities Hypertension 47 46.07 Coronary artery disease 33 32.35 Heart failure 29 28.43 Diabetes 19 18.63 Heart arrhythmia 10 9.80 Duration of smoking 29 28.43 0-5 years 22 21.57 5-10 years 9 8.82 10-15 years 20 19.61 Longer than 15 years 51 50.00 The number of cigarettes smoked per day 0-10 30 29.41 10-20 40 39.22 More than 20 33 31.37 Frequency of dyspnea exacerbati	Characteristics	N	%	
S-I0 years 28 27.45 10-I5 years 34 33.33 Longer than I5 years 23 22.55 Disease severity by GOLD 3 3 II 38 37 III 53 52 IV 8 8 Comorbidities 47 46.07 Coronary artery disease 33 32.35 Heart failure 29 28.43 Diabetes 19 18.63 Heart arrhythmia 10 9.80 Duration of smoking 5 10 19.61 Longer than I5 years 20 19.61 Longer than I5 years 51 50.00 The number of cigarettes smoked per day 0-10 30 29.41 10-20 40 39.22 More than 20 33 31.37 Frequency of dyspnea exacerbations during last month Once a day 41 40.20 Several times a week 25 24.51 Only after physical effort 19 18.63 Frequency of awakening due to COPD symptoms during the last month Once a week 28 27.45 Three nights a week or more often 57 55.88 None 17 16.67 Hospitalization due to exacerbation of COPD during the last 12 months Yes 62 60.78 No 36 35.29 The use of oxygen at home Yes 11 10.78	Duration of the disease			
10-15 years	0–5 years	17	16.67	
Longer than 15 years 23 22.55	5-10 years	28	27.45	
Disease severity by GOLD	10-15 years	34	33.33	
3	Longer than 15 years	23	22.55	
II	Disease severity by GOLD			
III	1	3	3	
IV	II	38	37	
Comorbidities Hypertension 47 46.07 Coronary artery disease 33 32.35 Heart failure 29 28.43 Diabetes 19 18.63 Heart arrhythmia 10 9.80 Duration of smoking 0-5 years 22 21.57 5-10 years 9 8.82 10-15 years 20 19.61 Longer than 15 years 51 50.00 The number of cigarettes smoked per day 0-10 30 29.41 10-20 40 39.22 More than 20 33 31.37 Frequency of dyspnea exacerbations during last month Once a day 17 16.67 More often than twice a day 41 40.20 Several times a week 25 24.51 Only after physical effort 19 18.63 Frequency of awakening due to COPD symptoms during the last month Once a week 28 27.45 Three nights a week or more often 57 55.88 Non	III	53	52	
Hypertension 47 46.07 Coronary artery disease 33 32.35 Heart failure 29 28.43 Diabetes 19 18.63 Heart arrhythmia 10 9.80 Duration of smoking	IV	8	8	
Coronary artery disease Heart failure Diabetes Heart arrhythmia Duration of smoking 0–5 years 5–10 years 10–15 years 10–15 years 10–15 years 10–10 years 10–10 years 10–10 30 29.41 10–20 40 39.22 More than 20 33 31.37 Frequency of dyspnea exacerbations during last month Once a day 17 16.67 More often than twice a day 41 40.20 Several times a week 25 24.51 Only after physical effort 19 18.63 Frequency of awakening due to COPD symptoms during the last month Once a week 28 27.45 Three nights a week or more often 57 55.88 None 17 16.67 Hospitalization due to exacerbations of COPD during the last 12 months Yes 62 60.78 No 40 39.22 Ability of taking inhaled medications Yes 66 66 64.71 No 36 35.29 The use of oxygen at home Yes 11 10.78	Comorbidities			
Heart failure 29 28.43 Diabetes 19 18.63 Heart arrhythmia 10 9.80 Duration of smoking	Hypertension	47	46.07	
Diabetes 19 18.63 Heart arrhythmia 10 9.80 Duration of smoking 0-5 years 22 21.57 5-10 years 9 8.82 10-15 years 20 19.61 Longer than 15 years 51 50.00 The number of cigarettes smoked per day 0-10 30 29.41 10-20 40 39.22 More than 20 33 31.37 Frequency of dyspnea exacerbations during last month Once a day 17 16.67 More often than twice a day 41 40.20 Several times a week 25 24.51 Only after physical effort 19 18.63 Frequency of awakening due to COPD symptoms during the last month Once a week 28 27.45 Three nights a week or more often 57 55.88 None 17 16.67 Hospitalization due to exacerbation of COPD during the last 12 months Yes Ability of taking inhaled medications 40 39.22 Ability of taking inhaled medications Yes 66 <td>Coronary artery disease</td> <td>33</td> <td>32.35</td>	Coronary artery disease	33	32.35	
Heart arrhythmia 10 9.80 Duration of smoking 22 21.57 0-5 years 20 19.61 5-10 years 20 19.61 Longer than 15 years 51 50.00 The number of cigarettes smoked per day 0-10 30 29.41 10-20 40 39.22 More than 20 33 31.37 Frequency of dyspnea exacerbations during last month Once a day 17 16.67 More often than twice a day 41 40.20 Several times a week 25 24.51 Only after physical effort 19 18.63 Frequency of awakening due to COPD symptoms during the last month Once a week 28 27.45 Three nights a week or more often 57 55.88 None 17 16.67 Hospitalization due to exacerbation of COPD during the last 12 months Yes 62 60.78 No 40 39.22 Ability of taking inhaled medications Yes 66 64.71 </td <td>Heart failure</td> <td>29</td> <td>28.43</td>	Heart failure	29	28.43	
Duration of smoking 22 21.57 0-5 years 9 8.82 10-15 years 20 19.61 Longer than 15 years 51 50.00 The number of cigarettes smoked per day 0-10 30 29.41 10-20 40 39.22 More than 20 33 31.37 Frequency of dyspnea exacerbations during last month 0nce a day 17 16.67 More often than twice a day 41 40.20 Several times a week 25 24.51 Only after physical effort 19 18.63 Frequency of awakening due to COPD symptoms during the last month Once a week 28 27.45 Three nights a week or more often 57 55.88 None 17 16.67 Hospitalization due to exacerbation of COPD during the last 12 months Yes 62 60.78 No 40 39.22 Ability of taking inhaled medications Yes 66 64.71 No 36 35.29 The use of oxygen at home 11 10.78	Diabetes	19	18.63	
Duration of smoking 0–5 years 22 21.57 5–10 years 9 8.82 10–15 years 20 19.61 Longer than 15 years 51 50.00 The number of cigarettes smoked per day 0–10 30 29.41 10–20 40 39.22 More than 20 33 31.37 Frequency of dyspnea exacerbations during last month 0 noce a day 17 16.67 More often than twice a day 41 40.20 Several times a week 25 24.51 Only after physical effort 19 18.63 Frequency of awakening due to COPD symptoms during the last month Once a week 28 27.45 Three nights a week or more often 57 55.88 None 17 16.67 Hospitalization due to exacerbation of COPD during the last 12 months 12 Yes 62 60.78 No 40 39.22 Ability of taking inhaled medications 40 39.22 The use of oxygen at home 11 10.78	Heart arrhythmia	10	9.80	
5–10 years 9 8.82 10–15 years 20 19.61 Longer than 15 years 51 50.00 The number of cigarettes smoked per day 0–10 30 29.41 10–20 40 39.22 More than 20 33 31.37 Frequency of dyspnea exacerbations during last month 0nce a day 17 16.67 More often than twice a day 41 40.20 Several times a week 25 24.51 Only after physical effort 19 18.63 Frequency of awakening due to COPD symptoms during the last month Once a week 28 27.45 Three nights a week or more often 57 55.88 None 17 16.67 Hospitalization due to exacerbation of COPD during the last 12 months Yes Ability of taking inhaled medications 40 39.22 Ability of taking inhaled medications Yes 66 64.71 No 36 35.29 The use of oxygen at home 11 10.78				
10-15 years	0–5 years	22	21.57	
Longer than 15 years 51 50.00 The number of cigarettes smoked per day 0–10 30 29.41 10–20 40 39.22 More than 20 33 31.37 Frequency of dyspnea exacerbations during last month 17 16.67 More a day 17 16.67 More often than twice a day 41 40.20 Several times a week 25 24.51 Only after physical effort 19 18.63 Frequency of awakening due to COPD symptoms during the last month Once a week 28 27.45 Three nights a week or more often 57 55.88 None 17 16.67 Hospitalization due to exacerbation of COPD during the last 12 months 12 Yes 62 60.78 No 40 39.22 Ability of taking inhaled medications Yes 66 64.71 No 36 35.29 The use of oxygen at home 11 10.78	5-10 years	9	8.82	
The number of cigarettes smoked per day 0–10	10-15 years	20	19.61	
0-10 30 29.41 10-20 40 39.22 More than 20 33 31.37 Frequency of dyspnea exacerbations during last month 0nce a day 17 16.67 More often than twice a day 41 40.20 Several times a week 25 24.51 Only after physical effort 19 18.63 Frequency of awakening due to COPD symptoms during the last month Once a week 28 27.45 Three nights a week or more often 57 55.88 None 17 16.67 Hospitalization due to exacerbation of COPD during the last 12 months Yes 62 60.78 No 40 39.22 Ability of taking inhaled medications Yes 66 64.71 No 36 35.29 The use of oxygen at home Yes 11 10.78	Longer than 15 years	51	50.00	
More than 20 33 31.37 Frequency of dyspnea exacerbations during last month Once a day 17 16.67 More often than twice a day 41 40.20 Several times a week 25 24.51 Only after physical effort 19 18.63 Frequency of awakening due to COPD symptoms during the last month Once a week 28 27.45 Three nights a week or more often 57 55.88 None 17 16.67 Hospitalization due to exacerbation of COPD during the last 12 months Yes 62 60.78 No 40 39.22 Ability of taking inhaled medications Yes 66 64.71 No 36 35.29 The use of oxygen at home Yes 11 10.78	The number of cigarettes smoked per da	у		
More than 20 Frequency of dyspnea exacerbations during last month Once a day More often than twice a day Several times a week Only after physical effort Once a wakening due to COPD symptoms during the last month Once a week Prequency of awakening due to COPD symptoms during the last month Once a week Three nights a week or more often Frequency of awakening due to COPD during the last 12 months Once a week None Frequency of awakening due to COPD during the last 12 months Anne Hospitalization due to exacerbation of COPD during the last 12 months Yes Ability of taking inhaled medications	0–10	30	29.41	
Frequency of dyspnea exacerbations during last month Once a day 17 16.67 More often than twice a day 41 40.20 Several times a week 25 24.51 Only after physical effort 19 18.63 Frequency of awakening due to COPD symptoms during the last month Once a week 28 27.45 Three nights a week or more often 57 55.88 None 17 16.67 Hospitalization due to exacerbation of COPD during the last 12 months Yes 62 60.78 No 40 39.22 Ability of taking inhaled medications Yes 66 64.71 No 36 35.29 The use of oxygen at home Yes 11 10.78	10–20	40	39.22	
Once a day 17 16.67 More often than twice a day 41 40.20 Several times a week 25 24.51 Only after physical effort 19 18.63 Frequency of awakening due to COPD symptoms during the last month Once a week 28 27.45 Three nights a week or more often 57 55.88 None 17 16.67 Hospitalization due to exacerbation of COPD during the last 12 months Yes 62 60.78 No 40 39.22 Ability of taking inhaled medications Yes 66 64.71 No 36 35.29 The use of oxygen at home Yes 11 10.78	More than 20	33	31.37	
More often than twice a day Several times a week Several times a week Only after physical effort I9 I8.63 Frequency of awakening due to COPD symptoms during the last month Once a week Z8 Z7.45 Three nights a week or more often None I7 I6.67 Hospitalization due to exacerbation of COPD during the last I2 months Yes 62 60.78 No 40 39.22 Ability of taking inhaled medications Yes 66 64.71 No 36 35.29 The use of oxygen at home Yes II I0.78	Frequency of dyspnea exacerbations duri	ng last month		
Several times a week Only after physical effort Only after physical effort I 9 I 8.63 Frequency of awakening due to COPD symptoms during the last month Once a week 28 27.45 Three nights a week or more often None I 7 I 6.67 Hospitalization due to exacerbation of COPD during the last I 2 months Yes 62 60.78 No 40 39.22 Ability of taking inhaled medications Yes 66 66 64.71 No 36 35.29 The use of oxygen at home Yes I 1 I 0.78	Once a day	17	16.67	
Several times a week Only after physical effort Only after physical effort I 9 I 8.63 Frequency of awakening due to COPD symptoms during the last month Once a week 28 27.45 Three nights a week or more often None I 7 I 6.67 Hospitalization due to exacerbation of COPD during the last I 2 months Yes 62 60.78 No 40 39.22 Ability of taking inhaled medications Yes 66 66 64.71 No 36 35.29 The use of oxygen at home Yes I 1 I 0.78	More often than twice a day	41	40.20	
Frequency of awakening due to COPD symptoms during the last month Once a week 28 27.45 Three nights a week or more often 57 55.88 None 17 16.67 Hospitalization due to exacerbation of COPD during the last 12 months Yes 62 60.78 No 40 39.22 Ability of taking inhaled medications Yes 66 64.71 No 36 35.29 The use of oxygen at home Yes 11 10.78		25	24.51	
Once a week 28 27.45 Three nights a week or more often 57 55.88 None 17 16.67 Hospitalization due to exacerbation of COPD during the last 12 months Yes 62 60.78 No 40 39.22 Ability of taking inhaled medications Yes 66 64.71 No 36 35.29 The use of oxygen at home Yes 11 10.78	Only after physical effort	19	18.63	
Once a week 28 27.45 Three nights a week or more often 57 55.88 None 17 16.67 Hospitalization due to exacerbation of COPD during the last 12 months Yes 62 60.78 No 40 39.22 Ability of taking inhaled medications Yes 66 64.71 No 36 35.29 The use of oxygen at home Yes 11 10.78		mptoms during th	e last month	
None I7 I6.67 Hospitalization due to exacerbation of COPD during the last I2 months Yes 62 60.78 No 40 39.22 Ability of taking inhaled medications Yes 66 64.71 No 36 35.29 The use of oxygen at home Yes II 10.78				
None I7 I6.67 Hospitalization due to exacerbation of COPD during the last I2 months Yes 62 60.78 No 40 39.22 Ability of taking inhaled medications Yes 66 64.71 No 36 35.29 The use of oxygen at home Yes I1 10.78	Three nights a week or more often	57	55.88	
Yes 62 60.78 No 40 39.22 Ability of taking inhaled medications Fee 66 64.71 No 36 35.29 The use of oxygen at home Fee 11 10.78	_	17	16.67	
Yes 62 60.78 No 40 39.22 Ability of taking inhaled medications Fee 66 64.71 No 36 35.29 The use of oxygen at home Fee 11 10.78	Hospitalization due to exacerbation of Co	OPD during the la	st 12 months	
Ability of taking inhaled medications Yes 66 64.71 No 36 35.29 The use of oxygen at home Yes II 10.78				
Yes 66 64.71 No 36 35.29 The use of oxygen at home 11 10.78	No	40	39.22	
Yes 66 64.71 No 36 35.29 The use of oxygen at home 11 10.78	Ability of taking inhaled medications			
No 36 35.29 The use of oxygen at home Yes II 10.78	-	66	64.71	
The use of oxygen at home Yes II 10.78				
Yes 11 10.78				
	, 6	11	10.78	
	No	91	89.22	

Abbreviations: FEV₁, forced expiratory volume in I second; FEV₁%N, forced expiratory volume in I second % of output value; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; N, number of patients; SD, standard deviation.

Pearson's correlation was used to evaluate associations between illness acceptance and the results of the TFI scale. This showed that a higher level of the physical and social domain of TFI correlated with a lower level of illness acceptance (Table 5).

Discussion

In our study, FS was found in 75.5% of elderly COPD patients. Acceptance of illness was moderate with a tendency to a lack of acceptance of the disease. A lower level of acceptance of illness was associated with a higher level of the physical and social domain of the TFI score. To the best of our knowledge, this is the first study that addresses frailty and its effect on illness acceptance in elderly patients with COPD; therefore, identification of the specific indicators that lead to the development of frailty in these patients may help to improve their quality of life and health care utilization, as well as reduce mortality and morbidity.

Earlier definitions of FS were based on the frailty model developed at the turn of the 1980s and 1990s. According to this model, the main symptoms of frailty included body weight loss, fatigue, slowing, weakness, and reduced physical activity. ^{18,19} In 2013, a group of six international associations dealing with frailty issues defined FS as:

A medical syndrome with multiple causes and contributors that is characterized by diminished strength, endurance, and reduced physiologic function that increases an individual's vulnerability for developing increased dependency and/or death.²⁰

At present, frailty becomes more and more important due to increasing life expectancy. Additionally, it is related to the increased risk of unfavorable health events, which are strongly associated with reduced physical fitness, an increased risk of falls, polypharmacy, comorbidities, decrease in cognitive function, and malnutrition.¹⁸ Possible pathophysiological causes of frailty include the predominance of catabolic processes, ongoing chronic inflammatory processes, immune system dysfunction, impaired neuroendocrine regulation, and metabolic disorders.8 On the one hand, frailty is a consequence of advanced age, but on the other, it is associated with multiple chronic diseases and as such, it increases disability, hospitalization rates, the cost of health care, and mortality. Only systematic assessment of FS enables risk stratification and the introduction of proper therapeutic strategies focused on the needs of elderly patients and their quality of life along with the effective use of health care resources.

Frailty impairs biopsychosocial functioning, which can affect the acceptance of illness among COPD patients. COPD is an irreversible and progressive disease. Patients with COPD experience intermittent exacerbations, characterized by acute deterioration in chronic dyspnea and functional limitation. They are more likely to be frail, as it is with people who

Table 3 Descriptive statistics for the questions of AIS

Questions from AIS questionnaire	Mean (SD)	Median (quartile I–III)
I have problems with adjusting to the limitations imposed by the disease	2.4 (0.97)	2 (2–3)
Due to my health condition, I am not able to do what I like the most	2.2 (0.95)	2 (2–3)
The disease makes me feel unwanted	3 (3.29)	3 (2–3)
Health problems make me more dependent on others than I would like to be	2.4 (1.11)	2 (2–3)
The disease makes me a burden for my family and friends	3.1 (1.10)	3 (2-4)
Due to my health condition I do not feel to be a really valuable man	2.4 (1.19)	2 (2–3)
I will never be as self-sufficient to the extent to which I would like to be	2.2 (1.20)	2 (1–3)
I believe people that stay with me are often embarrassed because of my disease	2.9 (0.92)	3 (2–3)
Overall level of acceptance of illness	20.6 (7.62)	19 (16–24)

Abbreviations: AIS, Acceptance of Illness Scale; SD, standard deviation.

have other advanced chronic diseases. 9,10,21 Chronic disease requires the patient to adapt to a number of limitations and participate in the treatment process. Diagnosis of chronic disease and loss of health demand from a patient that they implement multidimensional and continuous changes introduced in the scope of physical, mental, and social functioning. This process, similar to that in cancer diseases, is the way to acceptance not only associated with death, but of the need to adapt to the limitations imposed by chronic illness.

The degree of illness acceptance has been evaluated in many chronic diseases such as diabetes, arterial hypertension, renal failure, respiratory diseases, and diseases of the nervous system. The results of these studies indicate medium adaptation and acceptance of illness across many various chronic entities. Researchers claim that the fact of being chronically ill has an impact on the level of acceptance of illness and quality of life independent of diagnosis. 15,22 Adaptation to illness plays an important role in chronic diseases, which requires a different approach, including taking into account aspects such as patients' acceptance of illness. 23 Acceptance of illness is one of the most important stages in a patient's adaptation to his or her disease. It facilitates the adaptation process during which a patient adjusts to the new conditions of living with a disease.

In the present study, the mean level of acceptance of illness was 20.6 (on a range from 8 to 40). The results are

Table 4 Descriptive statistics for Tilburg frailty indicator

Part B components of frailty	Yes	Sometimes	No
B1 physical components			
II. Do you feel physically healthy?	19		83
12. Have you lost a lot of weight recently without wishing to do so?	32		69
Do you experience problems in your daily life due to			
13. difficulty in walking?	41		56
14. difficulty maintaining your balance?	30		64
15. poor hearing?	24		68
16. poor vision?	53		40
17. lack of strength in your hands?	77		18
18. physical tiredness?	98		3
B2 psychological components			
19. Do you have problems with your memory?	21	0	80
20. Have you felt down during the last month?	5	87	6
21. Have you felt nervous or anxious during the last month?	34	4	62
22. Are you able to cope with problems well?	47		52
B3 social components			
23. Do you live alone?	31		69
24. Do you sometimes miss having people around you?	40	14	48
25. Do you receive enough support from other people?	71		31
Frailty in the studied group M (SD); min-max	7.42 (2.24)	3–12	
Frailty syndrome	77		25
Physical domain M (SD); min-max	4.15 (1.95)	0–8	
Psychological domain M (SD); min-max	2.13 (1.07)	0–4	
Social domain M (SD); min-max	1.18 (0.89)	0–3	

Abbreviations: max, maximum; M, mean; min, minimum; SD, standard deviation.

Table 5 Correlation coefficients between the level of illness acceptance and results of TFI scale in the study group

Variables of TFI scale	Acceptance of illness scale
Physical domain of TFI	-0.36*
Psychological domain of TFI	0.06
Social domain of TFI	-0.24*
The level of frailty	-0.35

Note: *Statistical significance at a level of *P*<0.05. **Abbreviation:** TFI, Tilburg frailty indicator.

lower than those obtained by Niedzielski et al. In their study, the average level of acceptance of illness was 25 points, but was insignificantly lower in older patients and in those with earlier onset.²⁴ The worse acceptance of illness obtained in our study is due to the characteristics of the experimental group, which included elderly patients (mean age 63.2 years) with a long history of COPD (56% had been ill for 10 years and longer) and exacerbations.

FS was diagnosed in over 75% of our COPD patient group. Newman et al reported a 51% prevalence of frailty among patients with subclinical cardiovascular disease, but many of those patients were younger with less advanced disease. Park et al reported 57.8% of frailty among COPD patients; however, their study sample was not homogeneous and also included patients with chronic bronchitis. The frailty index in the present study accounted for a score of 7.42 (SD =2.24) scores, which indicates a high degree of frailty in COPD patients. The highest TFI score was reported in the physical domain – 4.15 (SD =1.19).

The present study shows that coexistence of FS negatively affects the level of acceptance of illness, especially in the social domain. Lack of support hampers adaptation to a disease. Additionally, deterioration of possibilities in terms of physical activity as measured by the TFI scale was a determinant of the decreased level of illness acceptance. Other researchers report similar observations. The association between acceptance of illness and patients' age, self-reliance in difficult situations and a sense of their own disease in patients with leukemia, ²⁶ as well as the living environment in elderly people²⁷ was revealed by other researchers. In a study by Jankowska-Polanska et al, the acceptance of a disease significantly impacts on the perception of quality of life in patients with COPD – the greater the acceptance, the higher the quality of life rating.²⁸

Conclusion

Elderly patients with severe COPD may be more prone to frailty and decreased acceptance of their disease in comparison to patients suffering from other chronic diseases. The level of frailty, especially in the physical and social domain, translates into lower acceptance of illness in this group of patients. Assessment and management of frailty in the care of older COPD patients are likely to significantly improve risk stratification and help personalize management, leading to better patient outcomes.

Disclosure

The authors report no conflicts of interest in this work.

References

- Mannino DM. Chronic obstructive pulmonary disease: definition and epidemiology. Respir Care. 2003;48(12):1185–1191.
- Zieliński J. [Chronic Obstructive Pulmonary Disease]. 4th ed. Wrocław: Górnicki Wydawnictwo Medyczne; 2007. Polish.
- Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013; 187(4):347–365.
- Petty TL. Definition, epidemiology, course, and prognosis of COPD. Clin Cornerstone. 2003;5(1):1–10.
- Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970–2002. JAMA. 2005;294(10):1255–1259.
- Hanania NA, Sharma G, Sharafkhaneh A. COPD in the elderly patient. Semin Respir Crit Care Med. 2010;31(5):596–606.
- 7. Panaszek B. [Bronchial Asthma and COPD Separate Approach to Diagnosis and Treatment in Elderly]. 1st ed. 2010:41–45. Polish.
- Uchmanowicz I, Lisiak M, Wontor R, et al. Frailty syndrome in cardiovascular disease: clinical significance and research tools. Eur J Cardiovasc Nurs. 2015;14(4):303–309.
- Blaum CS, Xue QL, Michelon E, Sembra RD, Fried LP. The association between obesity and the frailty syndrome in older women: the Women's Health and Aging Studies. *J Am Geriatr Soc.* 2005;53(6): 927–934
- Cigolle CT, Ofstedal MB, Tian Z, Blaum CS. Comparing models of frailty: the Health and Retirement Study. J Am Geriatr Soc. 2009;57(5): \$20, \$30.
- Newman AB, Gottdiener JS, McBurnie MA, Hirsch CH, Kop WJ, Tracy R. Associations of subclinical cardiovascular disease with frailty. J Gerontol A Biol Sci Med Sci. 2001;56(3):M158–M166.
- American Thoracic Society/European Respiratory Society Task Force. Standards for the Diagnosis and Management of Patients with COPD. New York: American Thoracic Society. [updated September 8, 2005]. Available from: http://www.thoracic.org/go/copd. Accessed March 21, 2016.
- Gobbens RJ, van Assen MA. Frailty and its prediction of disability and health care utilization: the added value of interviews and physical measures following a self-report questionnaire. *Arch Gerontol Geriatr*. 2012;55(2):369–379.
- Jurczyński Z. [Measurement Tools in the Promotion of Health and Psychooncology]. Warszawa: Pracownia Testów Psychologicznych; 2009:162–166. Polish.
- Felton BJ, Revenson TA, Hinrichsen GA. Stress and coping in the explanation of psychological adjustment among chronically ill adults. Soc Sci Med. 1984;18(10):889–898.
- Uchmanowicz I, Jankowska-Polanska B, Uchmanowicz B, Manulik S, Loboz-Grudzień K, Gobbens RJ. Validity and reliability of the Polish version of the Tilburg Frailty Indicator (TFI). *J Frailty Aging*. 2016; 5(1):27–32.
- Uchmanowicz I. [The influence of frailty syndrome on the assessment of illness acceptance in elderly patients with chronic heart failure]. J PsycholPharmacol. 2007;58(Suppl 5):647–655. Polish.

- Uchmanowicz I, Lisiak M, Jankowska-Polańska B. [Research instruments used in the assessment of the frailty syndrome]. *Gerontologia Polska*. 2014;22:1–8. Polish.
- Uchmanowicz I, Loboz-Rudnicka M, Szelag P, Jankowska-Polanska B, Loboz-Grudzień K. Frailty in heart failure. Curr Heart Fail Rep. 2014; 11(3):266–273.
- 20. Morley JE, Vellas B, van Kan GA, et al. Frailty consensus: a call to action. *J Am Med Dir Assoc*. 2013;14(6):392–397.
- Kurpas D, Mroczek B, Knap-Czechowska H, et al. Quality of life and acceptance of illness among patients with chronic respiratory diseases. *Respir Physiol Neurobiol*. 2013;187(1):114–117.
- 22. Jankowska-Polanska B, Ilko A, Wleklik M. [Influence the acceptance of the disease on quality of life of patients with hypertension]. *Arterial Hypertension*. 2014;18:1–8. Polish.
- Skrzypulec V, Drosdzol A, Nowosielski K. The influence of bronchial asthma on the quality of life and sexual functioning of women. *J Physiol Pharmacol*. 2007;58 Suppl 5:647–655.

- Niedzielski A, Humeniuk E, Tarkowski Z. [Level of disease acceptance in selected diseases]. Fam Med Prim Care Rev. 2005;7:823. Polish.
- Park SK, Richardson CR, Holleman RG, Larson JL. Frailty in people with COPD, using the National Health and Nutrition Evaluation Survey dataset (2003–2006). *Heart Lung*. 2013;42(3):163–170.
- Wiraszka G, Lelonek B. [The functioning of a patient with leukemia and acceptance of oncology disease]. Studia Med. 2008;10:21–26. Polish.
- Kaczmarczyk M. [The acceptance of the disease in older people living in different environments]. Stud Med. 2008;12:29–33. Polish.
- Jankowska-Polanska B, Kasprzyk M, Chudiak A. Relation between illness acceptance and quality of life in patients with chronic obstructive pulmonary disease (COPD). *Pneumonol Alergol Pol.* 2016;84(1): 3–10

International Journal of COPD

Publish your work in this journal

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols.

This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal

